映恩生物的估值逻辑迎来重塑,既是前沿技术平台的精准抢滩与系统布局,更得益于其在下一代技术范式中构筑的稀缺创新生态。又一明星药企冲刺“A+H”。2025年10月17日,映恩生物宣布,公司拟登陆科创板发行人民币普通股。半年前,这家ADC领域的创新药企成功登陆港交所主板。若此次科创板挂牌顺利,将为其快速推进的ADC研发管线注入强劲资金动力。五天后,映恩的研发日活动再次引起业内高度关注。活动上,映恩系统...
Source Link映恩生物的估值逻辑迎来重塑,既是前沿技术平台的精准抢滩与系统布局,更得益于其在下一代技术范式中构筑的稀缺创新生态。又一明星药企冲刺“A+H”。2025年10月17日,映恩生物宣布,公司拟登陆科创板发行人民币普通股。半年前,这家ADC领域的创新药企成功登陆港交所主板。若此次科创板挂牌顺利,将为其快速推进的ADC研发管线注入强劲资金动力。五天后,映恩的研发日活动再次引起业内高度关注。活动上,映恩系统...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.